Development of a Shigella conjugate vaccine targeting Shigella flexneri 6 that is immunogenic and provides protection against virulent challenge
Kelly M, Janardhanan J, Wagh C, Verma S, Charles R, Leung D, Kamruzzaman M, Pansuriya R, Chowdhury F, Vann W, Kaminski R, Khan A, Bhuiyan T, Qadri F, Kováč P, Xu P, Ryan E. Development of a Shigella conjugate vaccine targeting Shigella flexneri 6 that is immunogenic and provides protection against virulent challenge. Vaccine 2024, 42: 126263. PMID: 39217775, PMCID: PMC11409015, DOI: 10.1016/j.vaccine.2024.126263.Peer-Reviewed Original ResearchS. flexneri 6O-specific polysaccharideS. flexneri 3aShigella flexneri 2aShigella flexneri 6Component of lipopolysaccharideSerotype-specific monoclonal antibodiesS. sonneiShigella speciesFlexneri 2aShigella infectionShigella vaccineCarrier proteinHeavy chainBactericidal antibody responsesShigellaShigellosisVaccinated miceConjugate vaccineSerum of humansIgG responsesImmune responseLethal challengeAntibody responseIgM response